{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:42:27Z","timestamp":1783633347407,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2000,2,1]],"date-time":"2000-02-01T00:00:00Z","timestamp":949363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2000,2]]},"DOI":"10.1023\/a:1006481313747","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T02:03:28Z","timestamp":1040522608000},"page":"249-259","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of Early Response to SU101 Target-based Therapy in Patients with Recurrent Supratentorial Malignant Gliomas Using FDG PET and Gd-DTPA MRI"],"prefix":"10.1007","volume":"46","author":[{"given":"Andrei G.","family":"Vlassenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Thiessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Beattie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Malkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald G.","family":"Blasberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"262286_CR1","first-page":"1167","volume":"3","author":"LK Shawver","year":"1997","unstructured":"Shawver LK, Schwartz DP, Mann E, et al.: Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[(4-trifluoromethyl)-phenyl]-5-methylisoxazole-4-carboxamide. Clin Cancer Res 3: 1167-1177, 1997","journal-title":"Clin Cancer Res"},{"key":"262286_CR2","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1126\/science.2538922","volume":"243","author":"LT Williams","year":"1989","unstructured":"Williams LT: Signal transduction by the platelet-derived growth factor. Science 243: 1564-1570, 1989","journal-title":"Science"},{"key":"262286_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF01646843","volume":"68","author":"AJR Habenicht","year":"1990","unstructured":"Habenicht AJR, Salbach P, JanBen-Timmen U, Blattner C, Schettler G: Platelet-derived growth-factor-alpha growth factor with an expanding role in health and disease. Klin Wochenschr 68: 53-59, 1990","journal-title":"Klin Wochenschr"},{"key":"262286_CR4","first-page":"334","volume":"7","author":"G Plowman","year":"1994","unstructured":"Plowman G, Ullrich A, Shawver LK: Receptor tyrosine kinases as targets for drug intervention. Drug News and Perspective 7: 334-339, 1994","journal-title":"Drug News and Perspective"},{"key":"262286_CR5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01796261","volume":"44","author":"HM Cherwinski","year":"1995","unstructured":"Cherwinski HM, Byars N, Ballaron SJ, Nakano GM, Young JM, Ranson JT: Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 44: 317-322, 1995","journal-title":"Inflamm Res"},{"key":"262286_CR6","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bi952168g","volume":"35","author":"JP Davis","year":"1996","unstructured":"Davis JP, Cain GA, Pitts WJ, Magdola RL, Copeland RA: The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 35: 1270-1273, 1996","journal-title":"Biochemistry"},{"key":"262286_CR7","first-page":"385a","volume":"16","author":"MG Malkin","year":"1997","unstructured":"Malkin MG, Mason WP, Lieberman FS, et al.: Phase I study of SU101, a novel signal transduction inhibitor, in recurrent malignant glioma. Proc Amer Soc Clin Oncol 16: 385a, 1997","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"262286_CR8","first-page":"390a","volume":"17","author":"MG Malkin","year":"1998","unstructured":"Malkin MG, Rosen L, Lopez AM, et al.: Phase 2 study of SU101, a PDGF-R signal transduction inhibitor, in recurrent malignant glioma. Proc Amer Soc Clin Oncol 17: 390a, 1998","journal-title":"Proc Amer Soc Clin Oncol"},{"key":"262286_CR9","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1148\/radiology.166.3.2829270","volume":"166","author":"F Earnest","year":"1988","unstructured":"Earnest F, Kelly PJ, Scheithauer BW, et al.: Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166: 823-827, 1988","journal-title":"Radiology"},{"key":"262286_CR10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00004424-198705000-00002","volume":"22","author":"G Di Chiro","year":"1987","unstructured":"Di Chiro G: Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22: 360-371, 1987","journal-title":"Invest Radiol"},{"key":"262286_CR11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1148\/radiology.174.1.2294578","volume":"174","author":"AD Elster","year":"1990","unstructured":"Elster AD, Di Presio DA: Cranial postoperative site: assessment with contrast-enhanced MR imaging. Radiology 174: 93-98, 1990","journal-title":"Radiology"},{"key":"262286_CR12","first-page":"1083","volume":"8","author":"G Di Chiro","year":"1987","unstructured":"Di Chiro G, Oldfield E, Wright DC, et al.: Cerebral necrosis after radiotherapy and\/or intra-arterial chemotherapy for brain tumors: PET and neuropathologic studies. AJNR 8: 1083-1091, 1987","journal-title":"AJNR"},{"key":"262286_CR13","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/1097-0142(19880915)62:6<1074::AID-CNCR2820620609>3.0.CO;2-H","volume":"62","author":"JB Alavi","year":"1988","unstructured":"Alavi JB, Alavi A, Chawluk J, Kushner M, Powe J, Hickey W, Reivich M: Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62: 1074-1078, 1988","journal-title":"Cancer"},{"key":"262286_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1148\/radiology.195.1.7892494","volume":"195","author":"D Delbeke","year":"1995","unstructured":"Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM: Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195: 47-52, 1995","journal-title":"Radiology"},{"key":"262286_CR15","first-page":"515","volume":"14","author":"WK Davis","year":"1993","unstructured":"Davis WK, Boyko OB, Hoffman JM, Hanson MW, Schold SC, Burger PC, Friedman AH, Coleman RE: [18F]2-fluoro-2-deoxyglucose-positron emission tomography correlation of gadolinium-enhanced MR imaging of central nervous system neoplasia. AJNR 14: 515-523, 1993","journal-title":"AJNR"},{"key":"262286_CR16","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0360-3016(98)00183-7","volume":"41","author":"MW Gross","year":"1998","unstructured":"Gross MW, Weber WA, Feldmann HJ, Bartenstein P, Schwaiger M, Molls M: The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys 41: 989-995, 1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"262286_CR17","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1136\/jnnp.58.2.250","volume":"57","author":"WC Olivero","year":"1995","unstructured":"Olivero WC, Dulebohn SC, Lister JR: The use of PET in evaluating patients with primary brain tumors: is it useful? J Neurol Neurosurg Psychiatry 57: 250-252, 1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"262286_CR18","first-page":"407","volume":"19","author":"PE Ricci","year":"1998","unstructured":"Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP: Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR 19: 407-413, 1998","journal-title":"AJNR"},{"issue":"2","key":"262286_CR19","first-page":"235","volume":"27","author":"K Hamacher","year":"1986","unstructured":"Hamacher K, Coenen HH, Stocklin G: Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27(2): 235-238, 1986","journal-title":"J Nucl Med"},{"key":"262286_CR20","first-page":"263","volume-title":"Information Processing in Medical Imaging 1995","author":"A Collignon","year":"1995","unstructured":"Collignon A, Maes F, Delaere D, Vandermeulen D, Suetens P, Marchal G: Automated multi-modality image registration based on information theory. In: Bizais Y, Barillot C, Di Paola R (eds) Information Processing in Medical Imaging 1995. Kluwer Academic Publishers, Dordrecht, 1995, pp 263-274"},{"key":"262286_CR21","first-page":"1","volume":"34","author":"P Lindholm","year":"1993","unstructured":"Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H: Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med 34: 1-6, 1993","journal-title":"J Nucl Med"},{"key":"262286_CR22","first-page":"164","volume":"35","author":"CK Kim","year":"1994","unstructured":"Kim CK, Gupta NC, Chandramouli B, Alavi A: Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 35: 164-167, 1994","journal-title":"J Nucl Med"},{"key":"262286_CR23","first-page":"692","volume":"38","author":"AC Kole","year":"1997","unstructured":"Kole AC, Nieweg OE, Pruim J, Paans AMJ, Plukker JTM, Hoekstra HJ, Koops HS, Vaalburg W: Standardized uptake value and quantification of metabolism for breast cancer imaging with FDG and L-[1-11C]Tyrosine PET. J Nucl Med 38: 692-696, 1997","journal-title":"J Nucl Med"},{"key":"262286_CR24","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.32.12.1323","volume":"32","author":"G Di Chiro","year":"1982","unstructured":"Di Chiro G, DeLaPaz RL, Brooks RA: Glucose utilization of cerebral gliomas measured by [18]fluorodeoxyglucose and positron emission tomography. Neurology 32: 1323-1329, 1982","journal-title":"Neurology"},{"key":"262286_CR25","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3171\/jns.1985.62.6.0816","volume":"62","author":"NJ Patronas","year":"1985","unstructured":"Patronas NJ, Di Chiro G, Kufta C, Bairamian D, Kornblith PL, Simon R, et al.: Prediction of survival in glioma patients by means of positron emission tomography. J Neurosurg 62: 816-822, 1985","journal-title":"J Neurosurg"},{"key":"262286_CR26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF00151232","volume":"5","author":"K Mineura","year":"1987","unstructured":"Mineura K, Yasuda T, Kowada M, Ogawa T, Shishido F, Uemura K: Positron emission tomographic evaluation of radiochemotherapeutic effect on regional cerebral hemocirculation and metabolism in patients with gliomas. J Neuro-Oncol 5: 277-285, 1987","journal-title":"J Neuro-Oncol"},{"key":"262286_CR27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ana.410210111","volume":"21","author":"PC Phillips","year":"1987","unstructured":"Phillips PC, Dhawan V, Strother SC, Sidtis JJ, Evans AC, Allen JC, Rottenberg DA: Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: a positron emission tomographic study. Ann Neurol 21: 59-63, 1987","journal-title":"Ann Neurol"},{"key":"262286_CR28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00004728-198803000-00019","volume":"12","author":"T Ogawa","year":"1988","unstructured":"Ogawa T, Uemura K, Shishido F, Yamaguchi T, Murakami M, Inugami A, Kanno I, Sasaki H, Kato T, Hirata K, Kowada M, Mineura K, Yasuda T: Changes of cerebral blood flow, and oxygen and glucose metabolism following radiochemotherapy of gliomas: a PET study. J Comput Assist Tomogr 12: 290-297, 1988","journal-title":"J Comput Assist Tomogr"},{"key":"262286_CR29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<115::AID-CNCR17>3.0.CO;2-7","volume":"79","author":"FG Barker","year":"1997","unstructured":"Barker FG, Chang SM, Valk PE, Pounds TR, Prados MD: 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 79: 115-126, 1997","journal-title":"Cancer"},{"key":"262286_CR30","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ana.410330520","volume":"33","author":"TJ Janus","year":"1993","unstructured":"Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK: Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 33: 540-548, 1993","journal-title":"Ann Neurol"},{"key":"262286_CR31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/00004728-199307000-00001","volume":"17","author":"T Schifter","year":"1993","unstructured":"Schifter T, Hoffman JM, Hanson MW, Boyko OB, Beam C, Paine S, et al.: Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist Tomogr 17: 509-516, 1993","journal-title":"J Comput Assist Tomogr"},{"key":"262286_CR32","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2214\/ajr.163.6.7992747","volume":"163","author":"D Kahn","year":"1994","unstructured":"Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, et al.: Diagnosis of recurrent brain tumor: value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET. Am J Roentgenol 163: 1459-1465, 1994","journal-title":"Am J Roentgenol"},{"key":"262286_CR33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/00006231-198911000-00002","volume":"10","author":"KJ Langen","year":"1989","unstructured":"Langen KJ, Roosen N, Kuwert T, Herzog H, Kiwit JC, Rota-Kops E, et al.: Early effects of intra-arterial chemotherapy in patients with brain tumors studied with PET: preliminary results. Nucl Med Commun 10: 779-790, 1989","journal-title":"Nucl Med Commun"},{"key":"262286_CR34","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/00004728-199309000-00002","volume":"17","author":"T Holzer","year":"1993","unstructured":"Holzer T, Herholz K, Jeske J, Heiss WD: FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 17: 681-687, 1993","journal-title":"J Comput Assist Tomogr"},{"key":"262286_CR35","first-page":"12","volume":"34","author":"U Haberkorn","year":"1993","unstructured":"Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Ziegler S, Reisser C, Doll J, Helus F, van Kaick G: Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 34: 12-17, 1993","journal-title":"J Nucl Med"},{"key":"262286_CR36","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1097-0142(19941115)74:10<2836::AID-CNCR2820741015>3.0.CO;2-M","volume":"74","author":"O DeWitte","year":"1994","unstructured":"DeWitte O, Hildebrand J, Luxen A, Goldman S: Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 74: 2836-2842, 1994","journal-title":"Cancer"},{"key":"262286_CR37","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/archneur.1989.00520480044018","volume":"46","author":"JM Rozental","year":"1989","unstructured":"Rozental JM, Levine RL, Nickles RJ, Dobkin JA: Glucose uptake by gliomas after treatment: a positron emission tomographic study. Arch Neurol 46: 1302-1307, 1989","journal-title":"Arch Neurol"},{"key":"262286_CR38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF01050264","volume":"15","author":"JM Rozental","year":"1993","unstructured":"Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ: Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neuro-Oncol 15: 57-66, 1993","journal-title":"J Neuro-Oncol"},{"key":"262286_CR39","doi-asserted-by":"crossref","first-page":"19 246","DOI":"10.1074\/jbc.274.27.19246","volume":"274","author":"L Wang","year":"1999","unstructured":"Wang L, Hayashi H, Ebina Y: Transient effect of platelet-derived growth factor on GLUT4 translocation in 3T3-L1 adipocytes. J Biol Chem 274: 19 246-19 253, 1999","journal-title":"J Biol Chem"},{"key":"262286_CR40","first-page":"835","volume":"36","author":"KM Conricode","year":"1995","unstructured":"Conricode KM: Involvement of phosphatidylinositol 3-kinase in stimulation of glucose transport by growth factors in 3T3-L1 adipocytes. Biochem Mol Biol Int 36: 835-843, 1995","journal-title":"Biochem Mol Biol Int"},{"key":"262286_CR41","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1073\/pnas.92.4.1077","volume":"92","author":"S Kamohara","year":"1995","unstructured":"Kamohara S, Hayashi H, Todaka M, et al.: Platelet-derived growth factor triggers translocation of the insulinregulatable glucose transporter (type 4) predominantly through phosphatidylinositol 3-kinase binding sites on the receptor. Proc Natl Acad Sci USA 92: 1077-1081, 1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"262286_CR42","first-page":"529","volume":"67","author":"KH Plate","year":"1992","unstructured":"Plate KH, Breier G, Farrell CL, Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest 67: 529-534, 1992","journal-title":"Lab Invest"},{"key":"262286_CR43","doi-asserted-by":"crossref","first-page":"21 215","DOI":"10.1016\/S0021-9258(17)31950-6","volume":"269","author":"LM Strawn","year":"1994","unstructured":"Strawn LM, Mann E, Elliger SS, et al.: Inhibition of glioma by a truncated platelet-derived growth factor-beta receptor. J Biol Chem 269: 21 215-21 222, 1994","journal-title":"J Biol Chem"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006481313747.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1006481313747\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1006481313747.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T09:16:46Z","timestamp":1749633406000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1006481313747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,2]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,2]]}},"alternative-id":["262286"],"URL":"https:\/\/doi.org\/10.1023\/a:1006481313747","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,2]]}}}